ARROWHEAD PHARMACEUTICALS, INC.
For the period ended Jun 30, 2026. Filed Aug 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 4, 2026
Contents
Cover page
Show cover page
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 10-Q
(Mark One)
| x | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
|---|
For the quarterly period ended June 30, 2026
| o | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
|---|
For the transition period from to
Commission file number 001-38042
ARROWHEAD PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 46-0408024 |
|---|---|
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
177 E. Colorado Blvd, Suite 700
Pasadena, California 91105
(626)304-3400
(Address and telephone number of principal executive offices)
Former name, former address, and former fiscal year, if changed since last report: N/A
Securities registered pursuant to Section 12(b) of the Exchange Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
|---|---|---|
| Common Stock, par value $0.001 per share | ARWR | The Nasdaq Global Select Market |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x Noo
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x Noo
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large Accelerated Filer | x | Accelerated Filer | o |
|---|---|---|---|
| Non-Accelerated Filer | o | Smaller Reporting Company | o |
| Emerging Growth Company | o | ||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yeso Nox
The number of shares of the registrant’s common stock outstanding as of July 30, 2026 was 141,254,467.
| Page(s) | |
|---|---|
| PART I — FINANCIAL INFORMATION | |
| ITEM 1. FINANCIAL STATEMENTS | 1 |
| Consolidated Balance Sheets | 1 |
| Consolidated Statements of Operations and Comprehensive (Loss) Income | 2 |
| Consolidated Statements of Stockholders’ Equity | 3 |
| Consolidated Statements of Cash Flows | 5 |
| Notes to Consolidated Financial Statements | 7 |
| ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS | 34 |
| ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK | 44 |
| ITEM 4. CONTROLS AND PROCEDURES | 44 |
| PART II — OTHER INFORMATION | 46 |
| ITEM 1. LEGAL PROCEEDINGS | 46 |
| ITEM 1A. RISK FACTORS | 46 |
| ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS | 46 |
| ITEM 3. DEFAULTS UPON SENIOR SECURITIES | 46 |
| ITEM 4. MINE SAFETY DISCLOSURES | 46 |
| ITEM 5. OTHER INFORMATION | 46 |
| ITEM 6. EXHIBITS | 47 |
| SIGNATURE | 48 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.